{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:34:15Z","timestamp":1771572855781,"version":"3.50.1"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC) has traditionally relied on a multimodal approach, combining surgery, radiation therapy (RT), and chemotherapy. While chemotherapy plays a critical role in improving cure rates and functional outcomes, its substantial toxicity remains a major concern, particularly in older patients. These challenges are especially relevant for those who are unfit for chemotherapy or decline conventional concurrent chemoradiotherapy (CCRT), highlighting the need for alternative therapeutic options. Many patients are at high risk for severe side effects, often preventing them from completing the full chemotherapy regimen. This review explores alternative strategies to definitive CCRT of carcinomas of the larynx, hypopharynx and oropharynx, aiming to optimize treatment outcomes while minimizing toxicity. We discuss altered fractionation strategies as a promising alternative to conventional RT, offering a balance between treatment efficacy and quality of life. Additionally, we examine emerging approaches, including the combining of targeted therapies, immunotherapy, hyperthermia, photodynamic therapy and nanoparticle-based treatments with RT, which provide alternative or complementary options to traditional therapies in the management of LA-HNSCC.<\/jats:p>","DOI":"10.3389\/fonc.2025.1552337","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:26:34Z","timestamp":1745299594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy-free innovations in locally advanced head and neck cancer: a comprehensive review"],"prefix":"10.3389","volume":"15","author":[{"given":"Shatha","family":"Abu Taha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taher","family":"Abu Hejleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa","family":"ElHaddad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akram","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Sumaida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Bushehri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bassem","family":"Youssef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Alotain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Abu-Gheida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Aldehaim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majed","family":"Alghamdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Al Dohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maysa","family":"Al-Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadeem","family":"Pervez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoukri","family":"Temraz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Alrashidi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"El-Sheshtawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahid","family":"Al-Mandhari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Ghatasheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Hosni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.109282","article-title":"Global burden of head and neck cancers from 1990 to 2019","volume":"27","author":"Zhou","year":"2024","journal-title":"iScience"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-19-0038","article-title":"Incidence and demographic burden of HPV-associated oropharyngeal head and neck cancers in the United States","volume":"28","author":"Mahal","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/medsci11020042","article-title":"Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma","volume":"11","author":"Barsouk","year":"2023","journal-title":"Med Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e389810","DOI":"10.1200\/EDBK_389810","article-title":"Current treatment strategies and risk stratification for oral carcinoma","volume":"43","author":"Mohamad","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: A review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1269863","article-title":"Locally advanced head and neck squamous cell carcinoma treatment efficacy and safety: A systematic review and network meta-analysis","volume":"14","author":"Wang","year":"2023","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0973","article-title":"Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques","volume":"3","author":"Leeman","year":"2017","journal-title":"JAMA Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.radonc.2013.07.005","article-title":"Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma \u2013 A systematic review","volume":"110","author":"B\u00f8je","year":"2014","journal-title":"Radiother Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112809","article-title":"Management of older adults with locally advanced head and neck cancer","volume":"14","author":"Dickstein","year":"2022","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31416","article-title":"Tobacco smoking and alcohol drinking at diagnosis of head and neck cancer and all-cause mortality: results from head and neck 5000, a prospective observational cohort of people with head and neck cancer","volume":"143","author":"Beynon","year":"2018","journal-title":"Int J Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1255331","article-title":"(Panos) the role of chemotherapy in the management of patients with head and neck cancer","volume":"24","author":"Savvides","year":"2010","journal-title":"Semin Plast Surg"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.29.2.471","article-title":"Cell-cycle progression and response of germ cell tumors to cisplatin in vitro","volume":"29","author":"Mueller","year":"2006","journal-title":"Int J Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-04-0032","article-title":"Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of non-homologous end joining","volume":"3","author":"Boeckman","year":"2005","journal-title":"Mol Cancer Res MCR"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2021.01.013","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC group","volume":"156","author":"Lacas","year":"2021","journal-title":"Radiother Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70346-1","article-title":"Concomitant Chemoradiotherapy versus Acceleration of Radiotherapy with or without Concomitant Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): An Open-Label Phase 3 Randomised Trial","volume":"13","author":"Bourhis","year":"2012","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1200\/JCO.2004.08.021","article-title":"Final results of the 94-01 french head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma","volume":"22","author":"Denis","year":"2004","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2006.03.010","article-title":"Phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas","volume":"79","author":"Medina","year":"2006","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hed.20111","article-title":"Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer","volume":"27","author":"Beckmann","year":"2005","journal-title":"Head Neck"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers8020021","article-title":"Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas","volume":"8","author":"Hoek","year":"2016","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.077","article-title":"Relationship between cisplatin administration and the development of ototoxicity","volume":"24","author":"Rademaker-Lakhai","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/OP.22.00710","article-title":"Cisplatin-induced ototoxicity: A concise review of the burden, prevention, and interception strategies","volume":"19","author":"Chattaraj","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12335","article-title":"Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Staff","year":"2019","journal-title":"J Peripher Nerv Syst JPNS"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2167-c1","article-title":"Peripheral neurotoxicity of platinum-based chemotherapy","volume":"8","author":"Cavaletti","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv142","article-title":"Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin","volume":"45","author":"Hamauchi","year":"2015","journal-title":"Jpn J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.31557\/apjcc.2022.7.1.3-8","article-title":"Adherence to radiotherapy in the treatment of cancer patients: A tertiary care institute experience at punjab","volume":"7","author":"Singh","year":"2022","journal-title":"Asian Pac. J Cancer Care"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1594020","article-title":"Primary concurrent chemoradiation in head and neck cancers with weekly cisplatin chemotherapy: analysis of compliance, toxicity and survival","volume":"21","author":"Iqbal","year":"2017","journal-title":"Int Arch Otorhinolaryngol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1186\/s12885-015-1523-3","article-title":"Noncompliance to guidelines in head and neck cancer treatment; associated factors for both patient and physician","volume":"15","author":"Dronkers","year":"2015","journal-title":"BMC Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.5.5","article-title":"Barriers to adherence to cancer treatments among head and neck cancer patients","volume":"13","author":"Miller","year":"2022","journal-title":"J Adv Pract Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-2108-x","article-title":"Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in elderly patients with head and neck cancer","volume":"142","author":"Park","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1634\/theoncologist.2019-0406","article-title":"Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: A systematic review and meta-analysis","volume":"25","author":"Mohamed","year":"2020","journal-title":"Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3300","article-title":"E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group","volume":"35","author":"Marur","year":"2017","journal-title":"J Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30246-2","article-title":"Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study","volume":"18","author":"Chen","year":"2017","journal-title":"Lancet Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/annonc\/mdy522","article-title":"OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer","volume":"30","author":"Seiwert","year":"2019","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.08.014","article-title":"Interim futility results of NRG-HN005, A randomized, phase II\/III non-inferiority trial for non-smoking P16+ Oropharyngeal cancer patients","volume":"120","author":"Yom","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103243","article-title":"Decreasing treatment burden in HPV-related OPSCC: A systematic review of clinical trials","volume":"160","author":"Iorio","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-022-01297-0","article-title":"Targeted therapy for head and neck cancer: signaling pathways and clinical studies","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduction Targeting Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00383","article-title":"Cetuximab-containing combinations in locally advanced and recurrent or metastatic head and neck squamous cell carcinoma","volume":"9","author":"Taberna","year":"2019","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0433","article-title":"P16, HPV, and cetuximab: what is the evidence","volume":"22","author":"Bonner","year":"2017","journal-title":"Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71200-8","article-title":"Panitumumab plus Radiotherapy versus Chemoradiotherapy in Patients with Unresected, Locally Advanced Squamous-Cell Carcinoma of the Head and Neck (CONCERT-2): A Randomised, Controlled, Open-Label Phase 2 Trial","volume":"16","author":"Giralt","year":"2015","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2012.643864","article-title":"Zalutumumab in head and neck cancer","volume":"12","author":"Schick","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.oraloncology.2013.11.008","article-title":"Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients","volume":"50","author":"Reddy","year":"2014","journal-title":"Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4510","article-title":"Effect of standard radiotherapy with cisplatin vs accelerated radiotherapy with panitumumab in locoregionally advanced squamous cell head and neck carcinoma: A randomized clinical trial","volume":"3","author":"Siu","year":"2017","journal-title":"JAMA Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/cells13050413","article-title":"The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC)","volume":"13","author":"Wang","year":"2024","journal-title":"Cells"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.1509","article-title":"Immunology and immunotherapy of head and neck cancer","volume":"33","author":"Ferris","year":"2015","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.ijrobp.2022.09.003","article-title":"Radiotherapy with durvalumab vs. Cetuximab in patients with locoregionally advanced head and neck cancer and a contraindication to cisplatin: phase II results of NRG-HN004","volume":"114","author":"Mell","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B53","doi-asserted-by":"publisher","first-page":"S1310","DOI":"10.1016\/j.annonc.2021.08.2112","article-title":"LBA35 avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): randomized phase III GORTEC-REACH trial","volume":"32","author":"Bourhis","year":"2021","journal-title":"Ann Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus Standard-of-Care Chemoradiotherapy versus Chemoradiotherapy Alone in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S1399","DOI":"10.1016\/j.annonc.2022.08.029","article-title":"LBA5 Primary Results of the Phase III KEYNOTE-412 Study: Pembrolizumab (Pembro) with Chemoradiation Therapy (CRT) vs Placebo plus CRT for Locally Advanced (LA) Head and Neck Squamous Cell Carcinoma (HNSCC)","volume":"33","author":"Machiels","year":"2022","journal-title":"Ann Oncol"},{"key":"B56","unstructured":"Study details | Quad shot Radiotherapy in Combination With Immune Checkpoint Inhibition | ClinicalTrials.Gov"},{"key":"B57","unstructured":"Study details | Combining immunotherapy salvage surgery & IORT tx persistent\/recurrent head & Neck cancer | ClinicalTrials.Gov"},{"key":"B58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.7150\/ijms.10083","article-title":"Nanoparticle-based targeted therapeutics in head-and-neck cancer","volume":"12","author":"Wu","year":"2015","journal-title":"Int J Med Sci"},{"key":"B59","article-title":"Leaky tumor vessels: consequences for tumor stroma generation and for solid tumor therapy","author":"Dvorak","year":"1990","journal-title":"Prog Clin Biol Res"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Theranostics"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1189323","article-title":"The role of nanotherapy in head and neck squamous cell carcinoma by targeting tumor microenvironment","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S272902","article-title":"Gold nanoparticles as radiosensitizers in cancer radiotherapy","volume":"15","author":"Chen","year":"2020","journal-title":"Int J Nanomed"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1039\/C5NR07496G","article-title":"Actively targeted gold nanoparticles as novel radiosensitizer agents: an in vivo head and neck cancer model","volume":"8","author":"Popovtzer","year":"2016","journal-title":"Nanoscale"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.12.46","article-title":"Targeted nanoparticles for tumour radiotherapy enhancement\u2014the long dawn of a golden era","volume":"4","author":"Gargioni","year":"2016","journal-title":"Ann Transl Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1453753","article-title":"Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12951-015-0116-2","article-title":"Cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy","volume":"13","author":"Wang","year":"2015","journal-title":"J Nanobiotechnol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1038\/s41467-022-31859-3","article-title":"A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer","volume":"13","author":"Goldberg","year":"2022","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/07357907.2016.1213275","article-title":"A phase I\/II study of nab-paclitaxel, cisplatin, and cetuximab with concurrent radiation therapy for locally advanced squamous cell cancer of the head and neck","volume":"35","author":"Chun","year":"2017","journal-title":"Cancer Invest"},{"key":"B69","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12032-017-0884-7","article-title":"Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent\/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel","volume":"34","author":"Ley","year":"2017","journal-title":"Med Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7150\/ntno.81724","article-title":"Nanotheranostics-based management of head and neck cancer","volume":"7","author":"Chavda","year":"2023","journal-title":"Nanotheranostics"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3109\/02841868809090333","article-title":"The hazard of accelerated tumor clonogen repopulation during radiotherapy","volume":"27","author":"Withers","year":"1988","journal-title":"Acta Oncol Stockh Swed"},{"key":"B72","doi-asserted-by":"crossref","DOI":"10.5772\/60015","article-title":"The six rs of head and neck cancer radiotherapy","volume-title":"Contemporary Issues in Head and Neck Cancer Management","author":"Marcu","year":"2015"},{"key":"B73","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1470-2045(02)00906-3","article-title":"Radiotherapy for cancer of the head and neck: altered fractionation regimens","volume":"3","author":"Nguyen","year":"2002","journal-title":"Lancet Oncol"},{"key":"B74","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.1989.64","article-title":"Continuous, hyperfractionated, accelerated radiotherapy (CHART)","volume":"59","author":"Dische","year":"1989","journal-title":"British J Can."},{"key":"B75","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s13014-018-1133-8","article-title":"Accelerated vs. Conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: A meta-analysis","volume":"13","author":"Matuschek","year":"2018","journal-title":"Radiat Oncol Lond Engl"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi041","article-title":"Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer","volume":"35","author":"Isobe","year":"2005","journal-title":"Jpn J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031316","article-title":"Century of fractionated radiotherapy: how mathematical oncology can break the rules","volume":"23","author":"Ghaderi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B78","article-title":"Radiobiological basis for hyperfractionated radiation therapy","volume":"35","author":"Akimoto","year":"2008","journal-title":"Gan To Kagaku Ryoho"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30458-8","article-title":"Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis","volume":"18","author":"Lacas","year":"2017","journal-title":"Lancet Oncol"},{"key":"B80","unstructured":"Clinical Trials Database"},{"key":"B81","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.radonc.2020.03.025","article-title":"DAHANCA 28: A phase I\/II feasibility study of hyperfractionated, accelerated radiotherapy with concomitant cisplatin and nimorazole (HART-CN) for patients with locally advanced, HPV\/P16-negative squamous cell carcinoma of the oropharynx, hypopharynx, larynx and oral cavity","volume":"148","author":"Saks\u00f8","year":"2020","journal-title":"Radiother Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.026","article-title":"Randomized Controlled Trial of Hypofractionated vs. Normo-Fractionated Accelerated Radiation Therapy with or without Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma (HYPNO)","volume":"117","author":"Bentzen","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2012.00189","article-title":"PET\/CT in radiotherapy planning for head and neck cancer","volume":"2","author":"Newbold","year":"2012","journal-title":"Front Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2214\/AJR.17.18301","article-title":"Clinical practice in PET\/CT for the management of head and neck squamous cell cancer","volume":"209","author":"Goel","year":"2017","journal-title":"Am J Roentgenol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(03)00346-8","article-title":"Radiation treatment planning with an integrated positron emission and computer tomography (PET\/CT): A feasibility study","volume":"57","author":"Ciernik","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.01.014","article-title":"Variability of gross tumor volume delineation in head-and-neck cancer using CT and PET\/CT fusion","volume":"65","author":"Riegel","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B87","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1148\/radiol.2331030660","article-title":"Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen","volume":"233","author":"Daisne","year":"2004","journal-title":"Radiology"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.12.070","article-title":"Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer","volume":"68","author":"Madani","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B89","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ijrobp.2006.11.061","article-title":"Hypoxia dose painting by numbers: A planning study","volume":"68","author":"Thorwarth","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ijrobp.2007.06.039","article-title":"Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: A feasibility study","volume":"70","author":"Lee","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2014.10.006","article-title":"F18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy","volume":"45","author":"Rajendran","year":"2015","journal-title":"Semin Nucl Med"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2217\/iim.12.60","article-title":"FDG-PET\/CT imaging biomarkers in head and neck squamous cell carcinoma","volume":"4","author":"Paidpally","year":"2012","journal-title":"Imaging Med"},{"key":"B93","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.rcl.2021.05.012","article-title":"Novel tracers and radionuclides in PET imaging","volume":"59","author":"Mason","year":"2021","journal-title":"Radiol Clin North Am"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.77101","article-title":"Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: A report of randomized trial","volume":"6","author":"Huilgol","year":"2010","journal-title":"J Cancer Res Ther"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3109\/02656736.2010.503982","article-title":"Intracavity hyperthermia in nasopharyngeal cancer: A phase III clinical study","volume":"27","author":"Hua","year":"2011","journal-title":"Int J Hyperth"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.radonc.2019.05.002","article-title":"Hyperthermia with radiotherapy reduces tumour alpha\/beta: insights from trials of thermoradiotherapy vs radiotherapy alone","volume":"138","author":"Datta","year":"2019","journal-title":"Radiother Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/02656730310001619514","article-title":"Physiological mechanisms underlying heat-induced radiosensitization","volume":"20","author":"Vujaskovic","year":"2004","journal-title":"Int J Hyperth"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19092795","article-title":"Immunogenic effect of hyperthermia on enhancing radiotherapeutic efficacy","volume":"19","author":"Lee","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B99","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3109\/02656736.2015.1099746","article-title":"Hyperthermia and radiotherapy in the management of head and neck cancers: A systematic review and meta-analysis","volume":"32","author":"Datta","year":"2016","journal-title":"Int J Hyperth"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90154-6","article-title":"Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph nodes in stage IV head and neck patients","volume":"28","author":"Valdagni","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2024.41035","article-title":"ESHO 2\u201385. Hyperthermia as an adjuvant to radiation therapy in the treatment of advanced neck nodes: A randomized multicenter study by the european society for hyperthermic oncology","volume":"63","author":"Overgaard","year":"2024","journal-title":"Acta Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/02656736.2019.1653499","article-title":"Hyperthermia and immunotherapy: clinical opportunities","volume":"36","author":"Hurwitz","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10194404","article-title":"From basic mechanisms to clinical research: photodynamic therapy applications in head and neck Malignancies and vascular anomalies","volume":"10","author":"Ramsay","year":"2021","journal-title":"J Clin Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.5946\/ce.2013.46.1.24","article-title":"Photodynamic therapy (PDT): PDT mechanisms","volume":"46","author":"Allison","year":"2013","journal-title":"Clin Endosc"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-697-9_18","article-title":"Photodynamic therapy of head and neck cancers","volume":"635","author":"Biel","year":"2010","journal-title":"Methods Mol Biol Clifton NJ"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.626394","article-title":"Photodynamic therapy as an alternative therapeutic tool in functionally inoperable oral and oropharyngeal carcinoma: A single tertiary center retrospective cohort analysis","volume":"11","author":"Lambert","year":"2021","journal-title":"Front Oncol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.oraloncology.2016.01.013","article-title":"Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors","volume":"55","author":"Ahn","year":"2016","journal-title":"Oncol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/lsm.22802","article-title":"Photodynamic therapy in patients with head and neck squamous cell carcinoma","volume":"50","author":"Hosokawa","year":"2018","journal-title":"Lasers Surg Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.pdpdt.2019.101627","article-title":"Porfimer sodium-mediated photodynamic therapy in patients with head and neck squamous cell carcinoma","volume":"29","author":"Hosokawa","year":"2020","journal-title":"Photodiagn Photodyn Ther"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.691697","article-title":"Photodynamic therapy\u2014Current limitations and novel approaches","volume":"9","author":"Gunaydin","year":"2021","journal-title":"Front Chem"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1016\/s1011-1344(00)00082-8","article-title":"Measurement of the penetration depths of red and near infrared light in human \u201cEx vivo\u201d Tissues","volume":"57","author":"Stolik","year":"2000","journal-title":"J Photochem Photobiol B"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1385\/MO:18:4:243","article-title":"Treatment resistance of solid tumors: role of hypoxia and anemia","volume":"18","author":"Vaupel","year":"2001","journal-title":"Med Oncol Northwood Lond Engl"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1561","article-title":"Fractionated versus standard continuous light delivery in interstitial photodynamic therapy of dunning prostate carcinomas","volume":"13","author":"Xiao","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B114","unstructured":"A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC\n          \n          \n          \n          2024"},{"key":"B115","unstructured":"Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)\n          \n          \n          \n          2024"},{"key":"B116","unstructured":"Nanobiotix A Phase 3 Study of NBTXR3 Activated by Investigator&x27;s Choice of Radiotherapy Alone or Radiotherapy in Combination With Cetuximab for Platinum-Based Chemotherapy-Ineligible Elderly Patients With LA-HNSCC\n          \n          \n          2024"},{"key":"B117","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"B118","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/JCO.20.02072","article-title":"ARTSCAN III: A randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer","volume":"39","author":"Gebre-Medhin","year":"2021","journal-title":"J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - A trans-tasman radiation oncology group study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B120","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG oncology RTOG 1016): A randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized Phase III Trial of Concurrent Accelerated Radiation plus Cisplatin with or without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ijrobp.2013.12.027","article-title":"Final results of local-regional control and late toxicity of RTOG 9003: A randomized trial of altered fractionation radiation for locally advanced head and neck cancer","volume":"89","author":"Beitler","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.3925","article-title":"Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the radiation therapy oncology group 0129 trial: long-term report of efficacy and toxicity","volume":"32","author":"Nguyen-Tan","year":"2014","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2015.07.004","article-title":"The DAHANCA 6 randomized trial: effect of 6 vs 5 weekly fractions of radiotherapy in patients with glottic squamous cell carcinoma","volume":"117","author":"Lyhne","year":"2015","journal-title":"Radiother Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14361-9","article-title":"Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial","volume":"362","author":"Overgaard","year":"2003","journal-title":"Lancet"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70072-3","article-title":"Five versus Six Fractions of Radiotherapy per Week for Squamous-Cell Carcinoma of the Head and Neck (IAEA-ACC Study): A Randomised, Multicentre Trial","volume":"11","author":"Overgaard","year":"2010","journal-title":"Lancet Oncol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011201)92:11<2856::aid-cncr10132>3.0.co;2-6","article-title":"Alternating chemoradiotherapy versus partly accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck: results from a phase III randomized trial","volume":"92","author":"Corv\u00f2","year":"2001","journal-title":"Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/s0360-3016(02)03792-6","article-title":"Locoregionally Advanced Carcinoma of the Oropharynx: Conventional Radiotherapy vs. Accelerated Hyperfractionated Radiotherapy vs. Concomitant Radiotherapy and Chemotherapy\u2013a Multicenter Randomized Trial","volume":"55","author":"Olmi","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23865","article-title":"Conventional Radiotherapy versus Concurrent Chemoradiotherapy versus Accelerated Radiotherapy in Locoregionally Advanced Carcinoma of Head and Neck: Results of a Prospective Randomized Trial","volume":"38","author":"Ghosh-Laskar","year":"2016","journal-title":"Head Neck"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1552337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T05:26:37Z","timestamp":1745299597000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1552337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":129,"alternative-id":["10.3389\/fonc.2025.1552337"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1552337","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"article-number":"1552337"}}